Study · Randomized controlled trial · n = 61 · 2024

8 results

Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.

Gabe MBN, Breitschaft A, Knop FK, Hansen MR, Kirkeby K, Rathor N, Adrian CL

Diabetes, obesity & metabolism31 Jul 2024Cited by 36 (Europe PMC)

PMID39082206DOI10.1111/dom.15802PepBankPUB-39082206

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oral semaglutide 50 mg reduced ad libitum energy intake at week 20 compared with placebo.
In plain wordsIn adults with obesity, oral semaglutide reduced how much people ate at a meal compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseAd libitum energy intake, relative change from baseline at week 20
Study
n = 61
Comparator
Placebo
Analysis
Primary
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
50 mg once daily · oral · 20 weeksAs given in this study (human).
Measurements
Relative change in energy intake
−39.2 % points
semaglutide versus placebo
Source sentences
Summary
The relative change from baseline in ad libitum energy intake at week 20 (primary endpoint) was -39.2% points (95% confidence interval -59.0%, -19.4%) with semaglutide compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A clinical pharmacology, double-blind study was conducted in 61 adults with obesity randomized to once-daily oral semaglutide (dose-escalated to 50 mg) or placebo for 20 weeks.
Report a problemFND-3908220601
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity, body weight fell by 9.8% with oral semaglutide and by 1.5% with placebo.
In plain wordsIn adults with obesity, oral semaglutide lowered body weight more than placebo.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 61
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
50 mg once daily · oral · 20 weeksAs given in this study (human).
Measurements
Body weight reduction
9.8%
semaglutide
Body weight reduction
1.5%
placebo
Source sentences
Summary
Body weight was reduced by 9.8% with semaglutide and by 1.5% with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A clinical pharmacology, double-blind study was conducted in 61 adults with obesity randomized to once-daily oral semaglutide (dose-escalated to 50 mg) or placebo for 20 weeks.
Report a problemFND-3908220602
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oral semaglutide reduced hunger compared with placebo.
In plain wordsIn adults with obesity, oral semaglutide reduced hunger more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHunger ratings
Study
n = 61
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
50 mg once daily · oral · 20 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide reduced hunger, increased fullness and satiety, and was associated with fewer food cravings and better control of eating versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A clinical pharmacology, double-blind study was conducted in 61 adults with obesity randomized to once-daily oral semaglutide (dose-escalated to 50 mg) or placebo for 20 weeks.
Report a problemFND-3908220603
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oral semaglutide increased fullness compared with placebo.
In plain wordsIn adults with obesity, oral semaglutide increased the feeling of fullness more than placebo.
Peptide
Semaglutide
Outcome
IncreaseFullness ratings
Study
n = 61
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
50 mg once daily · oral · 20 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide reduced hunger, increased fullness and satiety, and was associated with fewer food cravings and better control of eating versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A clinical pharmacology, double-blind study was conducted in 61 adults with obesity randomized to once-daily oral semaglutide (dose-escalated to 50 mg) or placebo for 20 weeks.
Report a problemFND-3908220604
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oral semaglutide increased satiety compared with placebo.
In plain wordsIn adults with obesity, oral semaglutide increased the feeling of being satisfied after eating more than placebo.
Peptide
Semaglutide
Outcome
IncreaseSatiety ratings
Study
n = 61
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
50 mg once daily · oral · 20 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide reduced hunger, increased fullness and satiety, and was associated with fewer food cravings and better control of eating versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A clinical pharmacology, double-blind study was conducted in 61 adults with obesity randomized to once-daily oral semaglutide (dose-escalated to 50 mg) or placebo for 20 weeks.
Report a problemFND-3908220605
06HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oral semaglutide was associated with fewer food cravings than placebo.
In plain wordsIn adults with obesity, oral semaglutide was linked to fewer food cravings than placebo.
Peptide
Semaglutide
Outcome
DecreaseFood cravings
Study
n = 61
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
50 mg once daily · oral · 20 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide reduced hunger, increased fullness and satiety, and was associated with fewer food cravings and better control of eating versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A clinical pharmacology, double-blind study was conducted in 61 adults with obesity randomized to once-daily oral semaglutide (dose-escalated to 50 mg) or placebo for 20 weeks.
Report a problemFND-3908220606
07HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oral semaglutide was associated with better control of eating than placebo.
In plain wordsIn adults with obesity, oral semaglutide was linked to better control over eating than placebo.
Peptide
Semaglutide
Outcome
IncreaseControl of eating
Study
n = 61
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
50 mg once daily · oral · 20 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide reduced hunger, increased fullness and satiety, and was associated with fewer food cravings and better control of eating versus placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
A clinical pharmacology, double-blind study was conducted in 61 adults with obesity randomized to once-daily oral semaglutide (dose-escalated to 50 mg) or placebo for 20 weeks.
Report a problemFND-3908220607
08HumanRandomized controlled trialEfficacy outcome
In adults with obesity, oral semaglutide did not significantly change gastric emptying at week 20 compared with placebo.
In plain wordsIn adults with obesity, oral semaglutide did not significantly change how fast the stomach emptied, compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeGastric emptying at week 20
Study
n = 61
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
50 mg once daily · oral · 20 weeksAs given in this study (human).
Source sentences
Summary
No statistically significant difference in gastric emptying was observed at week 20.
1 context sentence(design, population, supporting numbers)
Summary · context
A clinical pharmacology, double-blind study was conducted in 61 adults with obesity randomized to once-daily oral semaglutide (dose-escalated to 50 mg) or placebo for 20 weeks.
Report a problemFND-3908220608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT07240246

Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults

FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovationn = 4024 Oct 2025 to 12 May 2026

GLP-1 · Obesity &Amp; Overweight · Dietary Supplement

Trial page ClinicalTrials.govUpdated 15 Jun 2026

CompletedPhase 1NCT05236517

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

Novo Nordisk A/Sn = 608 Feb 2022 to 7 Nov 2022

Obesity

Trial page ClinicalTrials.govUpdated 19 Sept 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.